Join the Zepbound group to help and get support from people like you.
Zepbound News (Page 2)
Continuing Tirzepatide Leads to Maintenance of Weight Reduction
MONDAY, Dec. 11, 2023 – Withdrawing tirzepatide after 36 weeks is associated with regain of lost weight, while weight loss is maintained with continued treatment, according to a study published...
Pounds Return Once Zepbound Users Quit the Weight-Loss Drug: Study
MONDAY, Dec. 11, 2023 – Folks who take the blockbuster weight-loss med tirzepatide (Zepbound) may regain much of the weight they lost soon after discontinuing it, new research shows. A trial funded...
Eli Lilly Says Its New Weight-Loss Drug, Zepbound, Is Now Available
WEDNESDAY, Dec. 6, 2023 – Eli Lilly has announced that its newly approved weight-loss medication, Zepbound, is now available for patients to take. "Today opens another chapter for adults living with...
New Weight-Loss Drug Zepbound Is Now Available, Company Says
WEDNESDAY, Dec. 6, 2023 – The newly approved weight-loss medication known as Zepbound is now available for patients to take, drug maker Eli Lilly announced Tuesday. "Today opens another chapter for...
Monthly News Roundup - November 2023
FDA Approves Lilly’s Zepbound for Chronic Weight Management In November, the U.S. Food and Drug Administration (FDA) approved Eli Lilly’s Zepbound (tirzepatide), a glucose-dependent insulinotropic pol...
Mounjaro Beats Ozempic for Weight Loss in Early Trial
WEDNESDAY, Nov. 29, 2023 (Healthday News) – The diabetes drug Mounjaro prompted more weight loss among overweight and obese adults than Ozempic did in a real-world setting, researchers report. Both...
FDA Approves New Diet Drug Zepbound, a Version of the Diabetes Med Mounjaro
THURSDAY, Nov. 9, 2023 – A second injectable diabetes drug has been approved for weight loss in overweight and obese adults, the U.S. Food and Drug Administration announced Wednesday. The...
FDA Approves New Diet Drug Zepbound, a Version of the Diabetes Med Mounjaro
WEDNESDAY, Nov. 8, 2023 – A second injectable diabetes drug has been approved for weight loss in overweight and obese adults, the U.S. Food and Drug Administration announced Wednesday. The...
Tirzepatide Tied to Substantial Additional Weight Loss After Lifestyle Intervention
WEDNESDAY, Nov. 8, 2023 – Tirzepatide provides substantial additional reduction in body weight in participants who already achieved ≥5.0 percent weight reduction with an intensive lifestyle i...
FDA Approves Zepbound (tirzepatide) for Chronic Weight Management
INDIANAPOLIS, Nov. 8, 2023 /PRNewswire/ – The U.S. Food and Drug Administration (FDA) approved Eli Lilly and Company's (NYSE: LLY) Zepbound™ (tirzepatide) injection, the first and only obesity t...
Ask a question
To post your own question to this support group, sign in or create an account.
Further information
Related condition support groups
Weight Loss (Obesity / Overweight)